Atyr PHARMA’s (ATYR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a $35.00 target price on the stock.

Atyr PHARMA Stock Down 2.2 %

Shares of ATYR traded down $0.04 during midday trading on Thursday, reaching $1.79. 323,049 shares of the stock were exchanged, compared to its average volume of 485,801. Atyr PHARMA has a twelve month low of $1.08 and a twelve month high of $2.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07. The stock has a market capitalization of $123.53 million, a P/E ratio of -2.03 and a beta of 1.25.

Atyr PHARMA (NASDAQ:ATYR) last issued its earnings results on Thursday, May 2nd. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.11 million. Analysts anticipate that Atyr PHARMA will post -0.89 EPS for the current year.

Insider Activity at Atyr PHARMA

In other Atyr PHARMA news, Director Paul Schimmel bought 52,300 shares of Atyr PHARMA stock in a transaction that occurred on Wednesday, July 24th. The shares were acquired at an average price of $1.93 per share, for a total transaction of $100,939.00. Following the acquisition, the director now owns 413,023 shares of the company’s stock, valued at approximately $797,134.39. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders own 3.70% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.